Cas:12408-33-2 aluminum,oxido(oxo)silicon manufacturer & supplier

Chemical Name:aluminum,oxido(oxo)silicon

CAS.NO:12408-33-2

Synonyms:aluminum oxido(oxo)silicon;Hydrogen aluminum silicate;Aluminium pentasilicon hydroxide undecaoxide;EINECS 235-644-3;Aluminum silicon hydroxide oxide (AlSi5(OH)O11);Synthetic hydrogen mordenite

Molecular Formula:AlH₃O₆Si₃

Molecular Weight:210.25800

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:120.39000

Exact Mass:209.90500

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like aluminum oxido(oxo)silicon chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Synthetic hydrogen mordenite physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 235-644-3 Use and application,Hydrogen aluminum silicate technical grade,usp/ep/jp grade.

Related News: Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes. aluminum,oxido(oxo)silicon manufacturer The U.K. government previously purchased more than 380 million rapid tests from Innova, to help set up programs capable of screening millions of people per day—in the run-up to offering free COVID-19 testing nationwide at least twice per week. aluminum,oxido(oxo)silicon supplier Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes. aluminum,oxido(oxo)silicon vendor The U.K. government previously purchased more than 380 million rapid tests from Innova, to help set up programs capable of screening millions of people per day—in the run-up to offering free COVID-19 testing nationwide at least twice per week. aluminum,oxido(oxo)silicon factory Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line.